Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack

Stroke Clinical Trial

Official title:

Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack: Adherence and Cardiovascular Events in the First Three Months

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02089074
• Other study ID #: 2012/1224a
• Status: Completed
• Phase: N/A
• First received: March 13, 2014
• Last updated: March 29, 2017
• Start date: November 2012
• Est. completion date: June 2016

Study information

• Verified date: March 2017
• Source: Norwegian University of Science and Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Use of drugs is an important factor in secondary prophylaxis after transient ischemic attack (TIA), but studies show that adherence to the prescribed drugs is often poor. This randomised controlled trial aims to investigate whether a systematic follow up of drug treatment using medication reconciliation, medication reviews and patient counselling by clinical pharmacists, improves adherence and/or decreases cardiovascular events the first three months and the first year after TIA. Patient satisfaction will also be compared between the two groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 265
• Est. completion date: June 2016
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Probable or possible transient ischemic attack

• Residing in Central Norway

• Examined within 2 weeks after the onset of symptoms

• Modified Rankin Scale 3 or less and living at home

• enrolled in the MIDNOR-TIA study NCT02038725

• Informed consent

Related Conditions & MeSH terms

• Ischemia
• Ischemic Attack, Transient
• Stroke

Intervention

Behavioral:
• Drug use counselling

Locations

Country	Name	City	State
Norway	Ålesund Sykehus	Ålesund
Norway	Kristiansund Sykehus	Kristiansund
Norway	Levanger Sykehus	Levanger
Norway	Molde Sykehus	Molde
Norway	Namsos Sykehus	Namsos
Norway	St Olavs Hospital	Trondheim

Sponsors (4)

Lead Sponsor	Collaborator
Norwegian University of Science and Technology	Helse Midt-Norge, St. Olavs Hospital, Sykehusapotekene i Midt Norge

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	adherence to drug treatment in secondary prevention after TIA	self reporting of adherence	3 months
Secondary	adherence to drug treatment in secondary prevention after TIA	self reporting of adherence	1 year
Secondary	Persistence	Persistence measured by control of filled prescriptions	3 months
Secondary	Incidence of stroke and cardiovascular events and deaths	Measured by using data from national health registries	3 months
Secondary	degree of disability or dependence in the daily activities	measured by modified Rankin Scale and indirectly by level of care	3 months
Secondary	patient satisfaction	Measured by using data from the Norwegian Stroke Registry	3 months
Secondary	Persistence	Persistence measured by control of filled prescriptions	1 year
Secondary	Incidence of stroke and cardiovascular events and deaths	Measured by using data from national health registries	1 year
Secondary	degree of disability or dependence in the daily activities	measured by modified Rankin Scale and indirectly by level of care	1 year
Secondary	patient satisfaction	Measured by using data from the Norwegian Stroke Registry	1 year

External Links

•   Related Info